Selumetinib
- Generic Name
- Selumetinib
- Brand Names
- Koselugo
- Drug Type
- Small Molecule
- Chemical Formula
- C17H15BrClFN4O3
- CAS Number
- 606143-52-6
- Unique Ingredient Identifier
- 6UH91I579U
- Background
Activation of the Raf-MEK-ERK signaling pathway is known to be implemented in several types of malignancies, thus, mitogen-activated protein kinase kinase (MEK) inhibitors such as selumetinib are important tools that can target the problematic overactivity of this pathway.
...
- Indication
Although selumetinib has been investigated for the treatment of several types of cancer, it is currently only indicated for the treatment of neurofibromatosis type 1 (NF1) in patients ≥2 years who have symptomatic, inoperable plexiform neurofibromas (PN).
- Associated Conditions
- Neurofibromatosis, type 1 (von Recklinghausen's disease)
- Associated Therapies
- -
An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1
- First Posted Date
- 2017-08-24
- Last Posted Date
- 2020-05-01
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT03259633
- Locations
- 🇺🇸
Research Site, New Orleans, Louisiana, United States
Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
- Conditions
- Advanced Malignant Solid NeoplasmAnn Arbor Stage III Childhood Non-Hodgkin LymphomaAnn Arbor Stage IV Childhood Non-Hodgkin LymphomaRefractory Primary Central Nervous System NeoplasmRecurrent Childhood Central Nervous System NeoplasmRecurrent NeuroblastomaRecurrent Childhood Non-Hodgkin LymphomaRecurrent Malignant Solid NeoplasmRefractory NeuroblastomaRefractory Malignant Solid Neoplasm
- Interventions
- First Posted Date
- 2017-07-11
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 21
- Registration Number
- NCT03213691
- Locations
- 🇺🇸
Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
🇺🇸Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸Banner Children's at Desert, Mesa, Arizona, United States
Selumetinib and Olaparib in Solid Tumors
- First Posted Date
- 2017-05-22
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 90
- Registration Number
- NCT03162627
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors
- Conditions
- Interventions
- First Posted Date
- 2017-03-29
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Target Recruit Count
- 10
- Registration Number
- NCT03095248
- Locations
- 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2016-12-28
- Last Posted Date
- 2018-03-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT03004105
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
- Conditions
- Interventions
- Drug: AdavosertibDrug: RibociclibDrug: OlaparibDrug: VistusertibDrug: NivolumabDrug: EnasidenibDrug: FutibatinibDrug: FadraciclibDrug: CytarabineDrug: TopotecanDrug: EverolimusDrug: CarboplatinDrug: IrinotecanDrug: CyclophosphamideDrug: SelumetinibDrug: LirilumabDrug: CeralasertibDrug: CapmatinibDrug: TemozolomideDrug: Dexamethasone
- First Posted Date
- 2016-06-24
- Last Posted Date
- 2023-05-30
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 460
- Registration Number
- NCT02813135
- Locations
- 🇩🇰
Rigshospitalet, Copenhagen, Denmark
🇫🇷Gustave Roussy, Villejuif, Val De Marne, France
🇳🇱Erasmus MC, Sophia Children's Hospital, Rotterdam, Netherlands
National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer
- First Posted Date
- 2016-01-27
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- University of Birmingham
- Target Recruit Count
- 423
- Registration Number
- NCT02664935
- Locations
- 🇬🇧
Royal Devon and Exeter Hospital, Exeter, United Kingdom
🇬🇧University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom
🇬🇧Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours
- First Posted Date
- 2015-10-27
- Last Posted Date
- 2019-11-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 58
- Registration Number
- NCT02586987
- Locations
- 🇺🇸
Research Site, Pittsburgh, Pennsylvania, United States
Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-09-11
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 117
- Registration Number
- NCT02546661
- Locations
- 🇬🇧
Research Site, Southampton, United Kingdom
Selumetinib and Paclitaxel as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer
- First Posted Date
- 2015-07-21
- Last Posted Date
- 2023-03-21
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 23
- Registration Number
- NCT02503358
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.